BioAtla, Inc. (BCAB)
NASDAQ: BCAB · Real-Time Price · USD
0.6701
-0.0293 (-4.19%)
Nov 3, 2025, 10:18 AM EST - Market open
BioAtla Revenue
BioAtla had revenue of $11.00M in the twelve months ending June 30, 2025. In the year 2024, BioAtla had annual revenue of $11.00M.
Revenue (ttm)
$11.00M
Revenue Growth
n/a
P/S Ratio
3.41
Revenue / Employee
$180,328
Employees
61
Market Cap
39.35M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 250.00K | -179.00K | -41.72% |
| Dec 31, 2020 | 429.00K | -4.77M | -91.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
BCAB News
- 11 days ago - BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society - GlobeNewsWire
- 14 days ago - BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025 - GlobeNewsWire
- 4 weeks ago - BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 - GlobeNewsWire
- 2 months ago - BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA - GlobeNewsWire
- 3 months ago - BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress - GlobeNewsWire
- 3 months ago - BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025 - GlobeNewsWire
- 3 months ago - BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting - GlobeNewsWire